AntibioTx to Present Phase I DECOLAD Results at the 26th EADV

COPENHAGEN, JUNE 02, 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders has been invited to present Phase I DECOLAD results at the Annual Congress of the European Academy of Dermatology and Venereology (EADV). The study enrolled 36 healthy volunteers and supported an excellent safety profile of ATx201. The 26th EADV runs from Wednesday 13 – Sunday 17 of September 2017 in Geneva, Switzerland. This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements. 13 Responses Pingback: how to get womens androxal and how much is it Pingback: how to buy enclomiphene generic alternatives Pingback: purchase rifaximin usa price Pingback: buying xifaxan cheap from usa Pingback: cheapest buy staxyn canada on sale Pingback: low cost avodart sun druggist Pingback: ordering dutasteride usa discount Pingback: cheapest buy flexeril cyclobenzaprine usa where to buy Pingback: cheap gabapentin canada shipping Pingback: online order fildena us overnight delivery Pingback: purchase itraconazole generic order Pingback: objednávejte kamagra z kanady Pingback: sans ordonnance kamagra pharmacie acheter cher Comments are closed.

The release as fetched from its publisher. uniontherapeutics.com ↗